Teva's 2nd-qtr 2007 net sales rise 10% to $2.39B
World generic giant Teva Pharmaceutical Industries says that its second-quarter net sales totaled $2.39 billion, up 10% over the like 2006 period, as net income reached $515.0 million from $489.0 million.
Commenting on the strong performance, Shlomo Yanai, chief executive of the Israeli firm, said that the results were driven by strong performances across all of the firm's business units and geographies, as well as by record-breaking sales of its branded mutiple sclerosis drug Copaxone (glatiramer acetate injection), and by a successful early launch of amlodipine/benazepril, the generic version of Swiss drug major Novartis' blood pressure medicine Lotrel.
Azilect (rasagiline), Teva's second innovative drug, continued its successful acceptance trend in the USA and Europe as a treatment for Parkinson's disease. Global in-market sales of the drug reached $28.0 million vs $6.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze